1. Institute of Medicine Committee on U, Eliminating R, Ethnic Disparities in Health C. In: Smedley BD, Stith AY, Nelson AR, editors. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington (DC): The National Academies Press; 2003.
2. Hershman DL, Buono DL, Malin J, et al. Patterns of use and risks associated with erythropoiesis-stimulating agents among medicare patients with cancer. JNCI J Natl Cancer Inst. 2009;101(23):1633–41.
3. Hershman DL, Neugut AI, Shim JJ, et al. Erythropoiesis-stimulating agent use after changes in medicare reimbursement policies. J Oncol Pract. 2014;10(4):264–9.
4. Li M, Schulz R, Chisholm-Burns M, et al. Racial/ethnic and gender disparities in the use of erythropoiesis-stimulating agents and blood transfusions: cancer management under Medicare’s reimbursement policy. J Manag Care Spec Pharm. 2020;26(11):1477–86.
5. Stafkey-Mailey D, Bennett C, Dickson M. Racial/ethnic disparities of erythropoiesis stimulating agent use among the insured poor: pre- and post-safety advisories. Blood. 2010;116(21):395.